Sigrid Van Bladel, PhD

Sigrid Van Bladel, Ph.D. joined Aberdare Ventures as a Venture Partner in 2011.

She previously was a Partner at New Enterprise Associates (NEA), a leading venture capital firm focusing on technology and healthcare start-ups, where she spent 18 years investing in biopharmaceutical and medical device companies.

During her investing career, Sigrid has a long, well established record of backing early-stage healthcare technology enterprises. Successful exits where she was an investor and Board member include Myogen (formerly NASDAQ: MYOG, acquired by Gilead); Kai Pharma (an Aberdare investment acquired by Amgen); Novacept (acquired by Cytyc/Hologic); SurgRx (acquired by Johnson and Johnson); Xcel Pharmaceuticals (acquired by Valeant Pharma); Appriva Medical (acquired by EV3/Covidien); and Spiration Inc. (acquired by Olympus Medical Systems).

For two years in a row during her tenure at NEA, Sigrid was included on Forbes Magazine’s Annual Midas List of the top 100 leading technology money makers, as only one of five women included on the list.

Sigrid Van Bladel, PhD is the Venture Partner at Aberdare Ventures. With a background in Venture Capital, Sigrid Van Bladel, PhD has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.